Latest Share Chat

REMOVE ADS

Immupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes

Get Live Data

4.30 -0.105 (-2.38%)

Bid:

4.21

Ask:

4.30

Spread: 0.09 (2.138%)

Market Cap: £26.83m

Last checked at -

Intraday Immupharma Share Chart

REMOVE ADS

Share Price Volatility

11 Dec 2019 12:49

RNS Number : 5515W

Immupharma PLC

11 December 2019

ImmuPharma PLC

("ImmuPharma" or the "Company")

SHARE PRICE VOLATILITY

ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company's share price and speculation concerning a possible fundraising. The Board can confirm that the Company is adequately funded and has no intention of raising funds.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

For further information please contact:

ImmuPharma PLC (www.immupharma.com) Tim McCarthy, Chairman	+ 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Vassil Kirtchev Stanford Capital Partners (Joint Broker) Patrick Claridge, John Howes SI Capital (Joint Broker) Nick Emerson	+44 (0) 203 368 8974 +44 (0) 203 815 8880 +44 (0) 1483 413500

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. For additional information about ImmuPharma please visit www.immupharma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCBDBDDLSBBGCB

Date		Source	Headline
25th May 2016	7:00 am	RNS	Holding(s) in Company
4th May 2016	7:01 am	RNS	Annual Financial Report & Notice of AGM
4th May 2016	7:00 am	RNS	Final Results
26th Apr 2016	7:00 am	RNS	Notice of Results
22nd Apr 2016	9:50 am	RNS	Holding(s) in Company
9th Mar 2016	7:00 am	RNS	First European Site Opens - Patient Recruitment
8th Mar 2016	11:10 am	RNS	Holding(s) in Company
7th Mar 2016	3:31 pm	RNS	Holding(s) in Company
1st Mar 2016	7:00 am	RNS	EIS and VCT Qualifying Status and Issue of Equity
29th Feb 2016	8:02 am	RNS	Holding(s) in Company
24th Feb 2016	12:35 pm	RNS	Issue of Equity
22nd Feb 2016	1:39 pm	RNS	Result of GM
15th Feb 2016	7:00 am	RNS	US PATIENTS COMMENCE DOSING IN PHASE III STUDY
5th Feb 2016	12:22 pm	RNS	Placing and Subscription Raises £8.3 million
5th Feb 2016	7:00 am	RNS	Proposed Placing and Subscription
21st Jan 2016	5:33 pm	RNS	Holding(s) in Company
15th Dec 2015	7:00 am	RNS	ImmuPharma & Simbec-Orion - Investigators Meeting
7th Dec 2015	7:00 am	RNS	Update on the progress of Lupuzor
30th Nov 2015	11:55 am	RNS	Holding(s) in Company
4th Nov 2015	8:26 am	RNS	Lupuzor Phase III Pivotal Trial Update
4th Nov 2015	7:00 am	RNS	Lupuzor Phase III Pivotal Trial Update
23rd Oct 2015	7:00 am	RNS	Directorate Change
30th Sep 2015	7:05 am	RNS	Directorate Change
30th Sep 2015	7:00 am	RNS	Interim Results
29th Jul 2015	7:00 am	RNS	Richard Warr
27th Jul 2015	7:00 am	RNS	TERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR
25th Jun 2015	7:00 am	RNS	Lupuzor's Founder Dr Slyviane Muller Awarded Medal
29th May 2015	12:50 pm	RNS	Result of AGM
6th May 2015	3:44 pm	RNS	Annual Report & Accounts
6th May 2015	7:02 am	RNS	Interim Board Change
30th Apr 2015	7:05 am	RNS	Directorate Change
30th Apr 2015	7:00 am	RNS	Preliminary Results
11th Feb 2015	12:02 pm	RNS	CANCER UPDATE: IPP-204106
27th Jan 2015	7:00 am	RNS	Enterprise Investment Scheme Status
22nd Jan 2015	7:00 am	RNS	Collaboration Agreement with Simbec-Orion
30th Oct 2014	11:10 am	RNS	Holding(s) in Company
28th Oct 2014	7:00 am	RNS	Holding(s) in Company
21st Oct 2014	7:00 am	RNS	Additional Listing - Conditional Placing
20th Oct 2014	7:00 am	RNS	ImmuPharma awarded EUR400,000 Grant
30th Sep 2014	7:05 am	RNS	Half Yearly Report
30th Sep 2014	7:00 am	RNS	LupuzorT Gears Up To Start Pivotal Phase III trial
27th Jun 2014	1:11 pm	RNS	Result of AGM
27th Jun 2014	7:00 am	RNS	Access to pioneering research in Bordeaux France
16th Jun 2014	7:00 am	RNS	NEW NUCANT PATENTS
23rd May 2014	7:00 am	RNS	Annual Financial Report
21st May 2014	7:00 am	RNS	Preliminary Results
6th May 2014	12:47 pm	RNS	Dr. Sylviane Muller - Presentation Abstract
23rd Apr 2014	7:00 am	RNS	Dr. S Muller, founder of Lupuzor presentation.
11th Apr 2014	7:00 am	RNS	ImmuPharma Sponsors the 2014 European Lupus Confer
14th Oct 2013	7:00 am	RNS	Additional Listing

Latest Share Chat

Immupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Intraday Immupharma Share Chart

Share Price Volatility

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending